Nucleix Ltd. Alternatives & Competitors
12 companies similar to Nucleix Ltd. — Developing cancer diagnostic panels based on epigenetic bio markers
Companies similar to Nucleix Ltd.
Exosome Diagnostics, a Bio-Techne brand
ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HG...
Waltham, United States
oncgnostics GmbH
Precision in Cancer Diagnostics
Jena, Germany
Valladolid, Spain
Breathonix Pte Ltd
Diagnostics Reimagined | Rapid Breath Tests for Disease Detection | Covid-19, Lung Cancer...
Singapore, Singapore
Rival Readout
Competing with Nucleix Ltd.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
LungLife AI
LungLife AI is transforming lung cancer diagnosis and management through AI-enabled analys...
Thousand Oaks, United Sta...
VisionGate, Inc.
Leading the Battle Against Lung Cancer through our Early Detection Technology
Phoenix, United States
RhoDx, Inc.
Reducing Cancer Morbidity and Mortality through Early Detection and Monitoring.
United States
Rarecells
Detect and defeat cancer from its start through a simple blood draw.
Paris, France
Beacon Biomedical
Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-...
Phoenix, United States
CellMax Life
Liquid biopsy company focused on cancer screening with a proprietary platform for detectin...
Sunnyvale, United States
EnLiSense LLC
EnLiSense biosensors and platform technologies enables tracking of WELLNESS to ILLNESS and...
Allen, United States
Cyted Health
Transforming access to digestive health for everyone, everywhere.
Cambridge, United Kingdom
About Nucleix Ltd.
Nucleix Ltd., founded in 2008 and headquartered in Israel, is making significant strides in the biotechnology sector with its development of cancer diagnostic panels based on epigenetic biomarkers. Positioning itself at the forefront of innovation, Nucleix leverages PCR-based epigenetics to detect cancers at early stag...
Development and Manufacturing of Non-Invasive Cancer Tests, Market Liquid Biopsy Assays, Research & Development in Cancer Detection, Collaboration with Leading Medical Institutions
High-Risk Individuals for Early Lung Cancer Detection, Patients with Primary and Recurrent Bladder Cancer, Healthcare Providers and Medical Centers
Cancer Diagnostics, Epigenetic Biomarkers, Liquid Biopsy, PCR-based Epigenetics, Methylation-based Identification, Non-invasive Testing, Bladder Cancer Detection, Lung Cancer Detection, Recurrent Cancer Monitoring, EpiCheck Platform, Medical Device CE-mark, FDA 510(k) Clearance, Urine-based Cancer Tests, Blood-based Cancer Tests, Molecular Diagnostic Tests
B2B, B2C, B2D
Product Sales, Licensing, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Nucleix Ltd.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Nucleix Ltd. on 22 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 2 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
